Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839087 | 0.98 | CYP3A4 (0.42) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL20686991 | 0.76 | RIPK1 (0.50) | CYP3A4MAPTKDM4EATMIDO1 | |
| Bromide SCHEMBL11038149 | 0.76 | CYP3A4 (0.50) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL14145021 | 0.76 | CYP3A4 (0.50) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL6132599 | 0.75 | HTT (0.50) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL11751773 | 0.74 | CYP2D6 (0.48) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL928816 | 0.74 | CYP3A4 (0.48) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL125129 | 0.73 | CYP3A4 (0.52) | CYP3A4MAPTKDM4EATMIDO1 | |
| SCHEMBL9779031 | 0.73 | HTT (0.45) | CYP3A4MAPTKDM4EATMIDO1 | |
| Hydrochloric Acid SCHEMBL538794 | 0.71 | CYP3A4 (0.56) | CYP3A4MAPTKDM4EATMIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | claimed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | claimed |
| US-11253478-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | claimed |
| EP-3755148-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNanoPharma (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2020-12-17 | — | — | US | claimed |
| WO-2019165240-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2019-08-29 | — | — | WO | claimed |
| US-20180250229-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-09-06 | — | — | US | claimed |
| US-9974748-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| US-9974746-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| US-9974747-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| WO-2003080024-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080023-A2 | FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | ELAN PHARMA INTERNATIONAL LTD. | 2003-09-25 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | ELAN PHARMA INTERNATIONAL LTD. | 2003-07-24 | — | — | US | claimed |
| US-20030095928-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2003-05-22 | — | — | US | claimed |
| WO-2003030872-A2 | COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-17 | — | — | WO | claimed |
| WO-2003024425-A1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | TUBAL3, TUBB6, TUBA1A | SLC6A2 825/4885SIGMAR1 1253/4885CYP3A4 1404/4885 |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | PACSIN2, MAP3K20, MAP3K2 | SLC6A2 2874/4885SIGMAR1 2060/4885CYP3A4 3419/4885 |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | NAPA, CD63, RPL36 | SLC6A2 773/4885SIGMAR1 259/4885CYP3A4 2022/4885 |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | LPO, LCT, CTSA | SLC6A2 2817/4885SIGMAR1 1877/4885CYP3A4 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.